Summary: The ability to assess antileukemic drug activity on primary patient samples is a powerful tool in determining potential drug targets and selection of therapeutic agents with biological and functional rationale. We previously established small molecule inhibitor screens for use on freshly isolated leukemia cells for this purpose. Here we describe a method that produces functional small molecule inhibitor screening results using cryopreserved primary acute myeloid leukemia cells. This method was established to take advantage of biorepositories containing archival material, such as those established by the Children's Oncology Group, and to enable validation of potential pathway dependencies uncovered by genomic analysis. Various conditions used to thaw and culture cryopreserved specimens were assessed for effect on viability, differentiation, and the ability to recapitulate sensitivity results obtained on fresh samples. The most reproducible results were obtained by quick-thawing and culturing samples in cytokine rich media before performing drug screens. Our data suggest that cytokine-enriched media aids in maintaining the viability and numbers required to perform functional analysis on cryopreserved leukemia cells. This method can aid in producing informative data on therapeutic targeting and precision medicine efforts in leukemia by making use of biorepositories and bio banks.
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Key Words: cryopreservation, small molecule inhibitor assays, acute myeloid leukemia (AML), biorepositories (J Pediatr Hematol Oncol 2017;39:e359-e366) C ryopreservation is a commonly used technique for the transport and preservation of mononuclear cells (MNC) isolated from bone marrow and peripheral blood. Cryopreserved MNCs have many uses including: clinical testing, correlative studies for clinical trials, inclusion in biorepositories, and posttransplant therapies. The Children's Oncology Group maintains 23,754 cryopreserved pediatric acute myeloid leukemia (AML) samples from 6872 unique patients in a biobank established to provide insight into rare childhood cancers. Genetic data have been obtained on 3393 of these tumors and our ability to identify inhibitor sensitivities has the ability to provide additional insight into novel mutation-drug associations in pediatric and adult AML. Initial attempts to thaw these samples were unsuccessful due to low viability and insufficient cell recovery. We sought to develop a method to optimize cell recovery from cryopreservation for use in small molecule inhibitor screens. Our overall goal was to facilitate functional validation of hypotheses generated from retrospective genomic analysis. Given the relative abundance of cryopreserved material our method could enable the expanded use of cryopreserved material from biorepositories and genetic studies.
Small molecule inhibitor panels can be used to uncover molecular targets essential for leukemia cell growth and have been successful in identifying effective therapies for patients. [1] [2] [3] Furthermore, additional clinically relevant information can be gleaned by combining genetic data with functionally important targets identified by small molecule inhibitor screens. 4 Furthermore, additional clinically relevant information can be gleaned by combining genetic data with functionally important targets identified by small molecule inhibitor screens. 4 Historically, we have used freshly isolated peripheral blood mononuclear cells to perform inhibitor screens. However, the length of time currently required to obtain sequencing panel results is on the order of weeks, which is more time than is feasible to maintain primary cells in culture, thus necessitating the use of cryopreserved samples to functionally validate genomic findings.
Cryopreservation has the potential to induce phenotypic changes and can drastically decrease cell viability. Changes induced by cryopreservation have been explored for B cells, [5] [6] [7] [8] T cells, 9,10 and other hematopoietic cell subpopulations. 11, 12 Therefore, evaluating the differences between freshly isolated and frozen cells is necessary to understand the potential effects that cryopreservation may have on downstream functional analyses.
We set out to overcome the low viability and poor cell recovery encountered with cryopreservation. Using media rich in hematopoietic growth factors, we tested the ability to support cell viability, maintain inhibitor sensitivity, and produce minimal changes in cell maturation markers. To empirically test each condition, cells were thawed and cultured in different mediums and assayed using a small molecule inhibitor panel. The results from inhibitor panel assays obtained from cryopreserved cells were compared with data obtained on freshly isolated cells. Concordance of functional results between fresh and frozen samples was used as a measure of reliability for each media. As distribution of cell maturation can be altered by cryopreservation 11, 12 and culturing in cytokine-enriched media, we assayed for alterations in specific cell surface maturation markers using fluorescence-activated cell sorting (FACS).
We report a method that maintains the highest viability and cell recovery, while minimizing changes in differentiation and functional screening results compared with fresh samples. This method supports the use of cryopreserved primary MNC in small molecule inhibitor screens and could be extended to enable the use of cryopreserved cells in other downstream functional assays.
MATERIALS AND METHODS

Cell Preparations
Plasma was isolated from whole blood by centrifuging at 2500 rpm for 10 minutes. The remaining blood was diluted with Iscove modified Dulbecco medium (IMDM): 1:1 for peripheral blood and 1:4 for bone marrow. MNC were separated using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Pittsburgh, PA). Using a 15 mL Falcon tube, 10 mL diluted blood or bone marrow was added dropwise to 4 mL Ficoll-paque and centrifuged at 1200 rpm for 20 minutes with no break. MNC were isolated from the buffy coat for testing. Cell counts and viability were recorded using Guava ViaCount (Millipore, Billerica). To create aliquots of frozen viable cells, 10 million Ficoll separated MNC were resuspended in 1 mL fetal bovine serum (FBS), 10% dimethyl sulfoxide, and gradually brought to −80°C, cooled at 1°C per minute, using Mr. Frosty and isopropanol (Nalgene, New York, NY) according to the manufacturer's specifications. After 24 hours, cells were transferred to liquid nitrogen for long-term storage.
Small Molecule Inhibitor Screens
Ficoll separated MNC were cultured in a 384-well plate small molecule inhibitor screen containing up to 20 tyrosine kinase inhibitors arrayed in 7-point dose gradients (Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/JPHO/A218). In brief, 15,000 cells were plated per well in Rosewell Park Memorial Institute (RPMI)-1640 and 10% FBS with 2% L-glutamine and 1% penicillin/streptomycin (R10) with β-mercaptoethanol and incubated at 37°C, 5% CO 2 for 72 hours. A tetrazoliumbased cell viability assay was performed using CellTiter 96 AQ ueous One Solution (MTS) (Promega, Madison, WI) We assessed the consistency of our method by comparing the AUCs of: a freshly isolated sample run in duplicate using the standard protocol for fresh cells (R 2 = 0.9746) (A); a cryopreserved sample run in duplicate prepared with our proposed thaw protocol (R 2 = 0.9794) (B); and comparison of a freshly isolated and cryopreserved counterpart from the same patient sample (R 2 = 0.8606) (C). AML indicates acute myeloid leukemia; AUC, area under the curve; CCM, cytokine culture media.
according to the manufacturer's protocol (Fig. 1A) . Absorbance was measured at 490 nm using a BioTek Synergy 2 plate reader at 5 and 24 hours. Absorbance measured between 0.2 to 1.0 arbitrary units (AU) were considered within an acceptable range. Mitochondrial metabolic activity readouts over a given dose curve were used to calculate area under the curve (AUC) values. In some cases, drugs may alter mitochondrial function without affecting cell viability but we have historically assessed mitochondrial potential and used it as a surrogate for cell viability in our assay. AUC values were used as a measure of sensitivity to a given inhibitor.
Thawing and Culturing of Frozen Cells
Frozen cells were gradually warmed to 37°C until a small ice pellet remained. Thaw media (25% FBS in IMDM) warmed to 37°C was added dropwise and the volume brought to 10 mL in a 15 mL conical tube. Cells were centrifuged at 1000 rpm for 10 minutes and media was aspirated. Addition of thaw media, centrifugation, and aspiration was repeated twice to remove residual dimethyl sulfoxide. Cells were resuspended in one of the following culture conditions: R10 (RPMI 10% FBS and 2% L-glutamine and 1% penicillin streptomycin), humanstroma-5 condition media (HS-5 stromal cells were cultured in R10 for 72 h, the media was collected and filtered using a 0.45 µM filter to remove residual cells, aliquots were frozen at −80°C for future use), stem cell media (SCM:IMDM containing 5% BIT9500, penicillin streptomycin, 1% L-glutamine, 10 −4 M β-mercaptoethanol, 50 pg/mL leukemia inhibitory factor, 1 ng/mL granulocyte colony stimulating factor, and interleukin-6, 0.2 ng/mL granulocyte macrophage stimulating factor, stem cell factor, and macrophage inflammatory protein-1α), or cytokine culture media (CCM: RPMI containing 25% FBS, 1% penicillin streptomycin, 1% L-glutamine, 10 ng/mL interleukin-3, stem cell factor, granulocyte colony stimulating factor, and granulocyte macrophage stimulating factor; Fig. 1B ). Cells were cultured at a concentration of 2 million viable cells/mL for 48 hours (37°C , 5% CO 2 ). After culturing, 5 to 7 million cells were centrifuged at 1000 rpm for 10 minutes, resuspended in R10, Samples from each unique patient are given the same sample ID. Total viable, total number of viable cells available before plating. Viability 24 hours, percent viable cells after thawing and culturing CCM for 24 hours. Type, the type of sample (peripheral blood or bone marrow) that was used to isolate cells for the assay. Percent blasts, percentage of circulating blasts in the patient at the time of sample acquisition as assessed by flow cytometry. Days frozen, number of days that the cryopreserved sample was stored in liquid nitrogen before thawing. AUC R 
Flow Cytometry
To examine the extent of cellular differentiation induced by cryopreservation and culturing, we assessed 4 conditions by FACS the relative levels of differentiation marker expression: (1) fresh cells cultured in R10; (2) fresh cells cultured in CCM; (3) cryopreserved cells cultured in CCM; and (4) freshly thawed cryopreserved cells. All conditions were run simultaneously and compensation was set for each marker based on fresh cells cultured in R10. Cryopreserved samples were either frozen for 24 hours, thawed, and cultured in CCM for 48 hours or frozen for 72 hours, thawed, and immediately analyzed by FACS. Fresh cells were cultured for the 72 hours it took to adequately freeze, thaw, and culture the cryopreserved subset. Half a million viable cells were stained and gated using viability dye (BD Biosciences, VB510). Samples were analyzed for cell surface markers: CD45 + , CD34 + , CD14 + , CD11b + , CD19 + , CD3 + , and CD13 + CD33 + (BD Biosciences) to quantify the relative number of different cell types under each condition, including leukocytes, stem cells, monocytes, granulocytes, B cells, T cells, and myeloid blasts, respectively (Supplemental Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/JPHO/A219). Data were analyzed using FlowJo (Ashland) and significance was measured using a 1-way analysis of variance Friedman test (α = 0.05) and 2-tailed nonparametric paired t test in Prism (Prism GraphPad CA).
RESULTS
Optimizing Culture Conditions for Cryopreserved Specimens
Culturing cryopreserved cells in cytokine-enriched media produced significantly better results than culturing in R10 alone before small molecule inhibitor screening ( Fig. 2A) . Cells cultured in cytokine-enriched media for 48 hours postthaw resulted in the highest level of cell viability ( Fig. 2A ; P < 0.05). Of the 3 cytokine mediums tested, CCM produced the highest concordance of drug responses when compared with results obtained on fresh samples (AUC; R 2 = 0.9251; Fig. 2B ), versus HS-5 conditioned media (R 2 = 0.7986; Fig. 2C ) and SCM (R 2 = 0.6978; Fig. 2D ). CCM proved to be the ideal media to progress with further testing due to high postthaw viability and concordance with fresh inhibitor results. Despite the high viability of HS-5 cultured media, initial testing on inhibitor concordance was not as strong as CCM. Because of limited sample availability, we opted to discontinue testing with media other than CCM. Attempts to remove dead cells via Ficoll separation were unable to improve the concordance of the small molecule inhibitor assay results, likely due to continuous cell death over the 72-hour assay time period. Samples with poor viability consistently exhibited lower absorbance when measured, suggesting they did not survive the 72-hour incubation period required for the assay. We thawed 36 cryopreserved primary AML samples from 17 individual patients to be cultured in CCM. From these 36 samples, 25 maintained cell viability > 70%, of these 17 maintained enough viable cells to plate on our inhibitor panel. Duplicate samples were tested to determine assay reproducibility between media types and sample status, fresh versus cryopreserved, a single representative sample run in all conditions of status and media type is shown in Figure. 3. We observed high concordance for duplicate plating of fresh samples assayed in R10 ( Fig. 3A; R 2 = 0.9746) and for duplicate plating of frozen samples thawed in CCM and then assayed in R10 ( Fig. 3B ; R 2 = 0.9794). High correlation between fresh and frozen sample results was also observed ( Fig. 3C ; R 2 = 0.8606). We tested a total of 17 samples cultured in CCM for 48 hours before plating in R10 on inhibitor plates, compare these results with data obtained on freshly plated cells, and obtained an average R 2 value of 0.6802 across all samples ( Table 1) . The most effective inhibitors, those with AUC values below 500 nM had higher concordance (R 2 = 0.7952) ( Table 1 ). For each of the 17 cryopreserved samples tested on the inhibitor panel, we annotated leukemia subtype, sample origin (peripheral blood or bone marrow), number of days frozen, and percent blasts at time of draw. None 1 factor significantly correlated with the concordance of results between fresh and frozen samples (Table 1) . We observed that plating cells immediately in R10 resulted in low concordant results between fresh and frozen cells, and rarely maintained viability > 70% after 48 hours.
For the 17 samples we tested, cryopreserved cells revived in CCM had an average AUC difference of 259.77 (AU) across all the drugs common between the fresh and frozen samples. Looking at inhibitors under 200 AUC from the fresh samples, the average difference between fresh and frozen inhibitors is 45.92 AU. "We observed no significant differences (P < 0.01) when comparing the inhibitor AUC results for the fresh and frozen samples using a paired t test Prism (Prism GraphPad CA) for 18 of 19 inhibitors." Significance was found between fresh and cryopreserved samples for the epidermal growth factor (EGFR) inhibitors gefitinib (n = 17, P = 0.0082) and lapatinib (n = 18, P = 0.0475), and a colony stimulating factor 1 receptor inhibitor (n = 13, P = 0.0074) (Fig. 4) .
We examined the effects of cytokine media on inhibitor results by comparing fresh and cryopreserved cells from the same sample cultured in R10 and CCM (Fig. 5) . Cryopreserved cells cultured in CCM had the highest concordance with fresh cells cultured in R10 (R 2 = 0.7195; Fig. 5A ). Fresh cells and cryopreserved cells cultured in R10 and CCM ( Fig. 5B ; R 2 = 0.5266 and Fig. 5C ; R 2 = 0.1503, respectively) and thawed and fresh cells cultured in R10 alone ( Fig. 5D ; R 2 = 0.1928) failed to produce higher levels of concordance. Thawed cells cultured in R10 and run on an inhibitor panel did not survive the 72-hour culture period and resulted in average absorbance plate readings under 0.2 AU resulting in low concordance (Figs. 5C, D) .
We calculated the average AUC of all inhibitors tested on fresh and cryopreserved, CCM thawed, cells, and performed a 2-way analysis of variance and t test using Prism test for significant differences. Of the 19 inhibitors tested, gefitinib, lapatinib, array-382 were found to be significantly different between fresh and cryopreserved cells.
Cytokine Effects on Differentiation Status Assessed by Flow Cytometry
To determine to what extent media and cryopreservation affected the differentiation status of the primary sample, we compared myeloid differentiation marker expression between freshly isolated cells and cryopreserved cells thawed in CCM and R10. Samples were stained with common leukocyte marker, CD45 . We observed no significant changes (α = 0.05) in marker expression across all conditions (Fig. 6 ).
DISCUSSION
Our experiments suggest that culturing cryopreserved cells in CCM for at least 24 hours prior plating can support the cell viability required for analysis using small molecule inhibitor assays. Culturing in CCM generated results that most closely recapitulated those obtained using freshly isolated cells while culturing in noncytokine-enriched media proved ineffective. On the basis of initial comparisons made by thawing cells in cytokine-enriched media and R10, we concluded that R10 was insufficient to support the viability of cryopreserved cells and thereby limited the recovery of cells from cryopreservation. We opted to not select for blasts to maintain a diversity of cell types in our assay to observe the effects of nonblasts on inhibitor sensitivity.
Of the inhibitors that showed a significant difference between fresh and cryopreserved cells, gefitinib and lapatinib were ineffective in all samples tested. This is consistent with the low occurrence of mutations in the EGFR family in leukemia. 13 However, EGFR inhibitors have been found effective in patients who have had non-small cell lung cancer concurrent with AML. 14, 15 Leukemias that may respond to EGFR inhibitors like gefitinib, additional work may be needed for analysis on cryopreserved cells. However, in the majority of leukemias that do not show sensitivity to this family of inhibitors, testing on cryopreserved cells may produce informative results. The colony stimulating factor 1 receptor inhibitor was also found to be significantly different between fresh and cryopreserved.
Importantly, limited changes in cell populations were observed through FACS analysis when cells were cultured in cytokine media for 24 or 72 hours suggesting cryopreservation may have had little effect on the different cell subpopulations within the specimen. The limited duration of time in cytokine media seems to be sufficient in maintaining similar types and relative numbers of cells in the fresh and frozen samples. With no significant change in marker expression, we concluded that similar cell populations were being tested when running fresh and cryopreserved MNC.
Although we recognize that functional testing on fresh samples is the most ideal situation, in many instances this is not possible. Cryopreserved specimens provide a valuable resource that can be used to gain biological and functional information. In addition, the wealth of samples maintained in biorepositories can contribute to advancing precision medicine efforts in AML and other rare hematological malignancies. More specifically, functional screening performed on cryopreserved material has the ability to link genomic and functional targets and can aid in identifying patient-specific therapeutic strategies. Although our work was focused on validation of results for small molecule inhibitor screens, we believe this method could also be useful for other assays that are able to capitalize on the wealth of data that could be obtained through the use of cryopreserved cells.
